Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 16,841 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions: Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b; Biological
Lead sponsor: AC Immune SA; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 13
States / cities: Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more

Conditions: 22q11.2 Deletion Syndrome
Interventions: NFC-1; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
Interventions: Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.; Diagnostic Test
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Metabolic Syndrome X, Insulin Resistance, Obesity, Cardiovascular Diseases
Interventions: Ortho Tri Cyclen; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Birmingham, Alabama • San Diego, California • Worcester, Massachusetts

Conditions: Dry Eye
Interventions: loteprednol etabonate ophthalmic suspension, 0.5%, vehicle of loteprednol etabonate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ondansetron, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 12
States / cities: Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more

Conditions: Sleep Apnea, Obstructive, Brain Injuries, Traumatic
Interventions: MI and CBT 4-session manualized intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions: Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: HIV Infections, Histoplasmosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more

Conditions: Obesity
Interventions: Whey protein supplementation with exercise, Non protein supplementation with exercise (control); Dietary Supplement · Other
Lead sponsor: Purdue University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Long Haul COVID-19, Post-Acute COVID-19 Syndrome, Anosmia, Olfaction Disorders
Interventions: Sodium Citrate, Normal Saline, Olfactory Training Kit - "The Olfactory Kit, by AdvancedRx"; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: asparaginase, daunorubicin hydrochloride, fludarabine phosphate, therapeutic hydrocortisone, allogeneic bone marrow transplantation, 3-dimensional conformal radiation therapy, filgrastim, cytarabine, idarubicin, dexamethasone, thioguanine, etoposide, methotrexate, cyclophosphamide, aldesleukin, busulfan; Drug · Procedure · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Dravet Syndrome
Interventions: ZX008 (Fenfluramine Hydrochloride), Matching Placebo; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more

Conditions: Rett Syndrome
Interventions: dextromethorphan, placebo; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 1 Year to 10 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Mucopolysaccharidosis I
Interventions: No Intervention; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Dry Eye
Interventions: Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops, Blink Tears, GenTeal Moderate Lubricant Eye Drops; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Deep Vein Thrombosis, Post-thrombotic Syndrome
Interventions: EkoSonic® Endovascular System, Alteplase; Device · Biological
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 22
States / cities: Los Angeles, California • Aurora, Colorado • Darien, Connecticut + 18 more

Conditions: Epilepsy
Interventions: ezogabine/retigabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more

Conditions: Breast, Mastectomy, Segmental
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Autistic Disorder, Pervasive Developmental Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Rett Syndrome
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Acute Respiratory Failure, Acute Respiratory Infection, Acute Respiratory Distress Syndrome
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
Interventions: Mirabegron 50 MG, Mirabegron 25 MG; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

Non-invasive Functional Assessment and Pathogenesis of Morquio A

Oral Contraceptives in the Metabolic Syndrome

An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Feasibility of Improving Sleep Apnea Treatment Adherence After Brain Injury

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs

Resistance and Aerobic Exercise With Nutritional Supplementation in Men and Women

Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

Placebo Controlled Trial of Dextromethorphan in Rett Syndrome

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

Long Term Follow-Up for RGX-111

Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System

Study in Pediatric Subjects With Epilepsy

Post-Breast Procedure Pain Syndrome Study

Advanced Grandparental Age as a Risk Factor for Autism

Airway Inflammatory Response During Illness in Children With Respiratory Failure

Using Mirabegron to Increase BP in Patients With POTS